Biomarkers of systemic XXXX and @entity308 and @entity1295 in moderate clinically stable @entity1030 .

@entity1 @entity32 @entity650 @entity308 @entity310 @entity1295 @entity1030 @entity1851
INTRODUCTION: @entity1030 is an @entity32 with major co-morbidities. It has recently been suggested that @entity308 may be the result of systemic @entity32 . We aimed to explore the association between systemic @entity32 and symptoms of @entity308 and @entity1295 in @entity1 with mainly moderate and clinically stable @entity1030 using a range of inflammatory biomarkers, 2 @entity308 and 2 @entity1295 scales. METHOD: We assessed 120 @entity1 with moderate @entity1030 (FEV1% 52, @entity1 62%, age 66). @entity308 was assessed using the BASDEC and CES-D scales. Fatigue was assessed using the Manchester @entity1295 (MCFS) and the Borg scale before and after 6MWT. We measured systemic @entity310 , @entity1851 , @entity310 -R1, @entity310 -R2 and @entity650 . RESULTS: A multivariate linear model of all biomarkers showed that @entity310 only had a positive correlation with BASDEC @entity308 score (p = 0.007). @entity310 remained positively correlated with @entity308 (p = 0.024) after further adjusting for @entity310 -R1, @entity310 -R2, 6MWD, FEV1%, and pack-years. Even after adding the MCFS score, body mass and body composition to the model @entity310 was still associated with the BASDEC score (p = 0.044). Furthermore, @entity1 with higher @entity310 level (> 3 pg/ml, n = 7) had higher mean CES-D @entity308 score than the rest of the sample (p = 0.03). Borg @entity1295 score at baseline were weakly correlated with @entity310 and @entity1851 , and with @entity310 only after 6MWT. @entity1 with higher @entity310 had more @entity1295 after 6MWD (p = 0.054). CONCLUSION: This study indicates a possible association between @entity310 and two frequent and major co-morbidities in @entity1030 ; i.e., @entity308 and @entity1295 .
